Literature DB >> 34050584

Report of the 22nd nationwide follow-up Survey of Primary Liver Cancer in Japan (2012-2013).

Masatoshi Kudo1,2, Namiki Izumi1,3, Norihiro Kokudo1,4, Michiie Sakamoto1,5, Shuichiro Shiina1,6, Tadatoshi Takayama1,7, Ryosuke Tateishi1,8, Osamu Nakashima1,9, Takamichi Murakami1,10, Yutaka Matsuyama1,11, Arata Takahashi1,12,13, Hiroaki Miyata1,12,13, Shoji Kubo1,14.   

Abstract

In the 22nd Nationwide Follow-up Survey of Primary Liver Cancer in Japan, data from 21 155 newly registered patients and 43 041 previously registered follow-up patients were compiled from 538 institutions over a 2-year period from January 1, 2012 to December 31, 2013. Basic statistics compiled for patients newly registered in the 22nd survey were cause of death, past medical history, clinical diagnosis, imaging diagnosis, treatment-related factors, pathologic diagnosis, recurrence status and autopsy findings. Compared with the previous 21st survey, the population of patients with hepatocellular carcinoma (HCC) was older at the time of clinical diagnosis, had more female patients, more patients with non-B non-C HCC, smaller tumor diameter and was more frequently treated with hepatectomy. Cumulative survival rates were calculated for HCC, intrahepatic cholangiocarcinoma, and combined hepatocellular cholangiocarcinoma (combined HCC and intrahepatic cholangiocarcinoma) by treatment type and background characteristics for patients newly registered between 2002 and 2013 whose final outcome was survival or death. Median overall survival and cumulative survival rates for HCC were calculated by dividing patients by combinations of background factors (number of tumors, tumor diameter or Child-Pugh grade) and by treatment type (hepatectomy, radiofrequency ablation therapy, transcatheter arterial chemoembolization, hepatic arterial infusion chemotherapy and systemic therapy). The same values were also calculated according to registration date by dividing patients newly registered between 1978 and 2013 into five time period groups. The data obtained from this nationwide follow-up survey are expected to contribute to advancing clinical research and treatment of primary liver cancer worldwide.
© 2022 The Authors. Hepatology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Hepatology.

Entities:  

Keywords:  combined hepatocellular cholangiocarcinoma; cumulative survival rate; hepatocellular carcinoma; intrahepatic cholangiocarcinoma; liver cancer study group of Japan; nationwide follow-up survey; nationwide survey

Year:  2022        PMID: 34050584     DOI: 10.1111/hepr.13675

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  10 in total

1.  Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL).

Authors:  Kazuya Okushin; Ryosuke Tateishi; Arata Takahashi; Koji Uchino; Ryo Nakagomi; Takuma Nakatsuka; Tatsuya Minami; Masaya Sato; Mitsuhiro Fujishiro; Kiyoshi Hasegawa; Yuichiro Eguchi; Tatsuya Kanto; Shoji Kubo; Hitoshi Yoshiji; Hiroaki Miyata; Namiki Izumi; Masatoshi Kudo; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2022-07-05       Impact factor: 6.772

Review 2.  Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma.

Authors:  Xing Chen; Jinpeng Du; Jiwei Huang; Yong Zeng; Kefei Yuan
Journal:  J Clin Transl Hepatol       Date:  2022-01-04

3.  Intrahepatic Cholangiocarcinoma With Neither Intrahepatic Metastasis Nor Lymph Node Metastasis Is the Optimal Indication for Hepatectomy With Adjuvant Therapy.

Authors:  Shun-Ichi Ariizumi; Masakazu Yamamoto; Yoshihito Kotera; Ryota Higuchi; Shingo Yamashita; Takaaki Kato; Yoshihiro Hirata; Satoshi Katagiri; Goro Honda; Hiroto Egawa
Journal:  Cancer Diagn Progn       Date:  2022-03-03

Review 4.  Favorable control of hepatocellular carcinoma with peritoneal dissemination by surgical resection using indocyanine green fluorescence imaging: a case report and review of the literature.

Authors:  Yuma Tani; Hiroki Sato; Ryuichi Yoshida; Kazuya Yasui; Yuzo Umeda; Kazuhiro Yoshida; Tomokazu Fuji; Kenjiro Kumano; Kosei Takagi; Masaaki Kagoura; Takahito Yagi; Toshiyoshi Fujiwara
Journal:  J Med Case Rep       Date:  2022-06-06

5.  Morbidity, Prognostic Factors, and Competing Risk Nomogram for Combined Hepatocellular-Cholangiocarcinoma.

Authors:  Xiaoyuan Chen; Yiwei Lu; Xiaoli Shi; Xuejiao Chen; Dawei Rong; Guoyong Han; Long Zhang; Chuangye Ni; Jie Zhao; Yun Gao; Xuehao Wang
Journal:  J Oncol       Date:  2021-12-10       Impact factor: 4.375

6.  Epidemiological and Clinical Characteristics of Five Rare Pathological Subtypes of Hepatocellular Carcinoma.

Authors:  Xiaoyuan Chen; Yiwei Lu; Xiaoli Shi; Guoyong Han; Long Zhang; Chuangye Ni; Jie Zhao; Yun Gao; Xuehao Wang
Journal:  Front Oncol       Date:  2022-04-08       Impact factor: 5.738

7.  Promising role of liver transplantation in patients with combined hepatocellular-cholangiocarcinoma: a propensity score matching analysis.

Authors:  Xiaoyuan Chen; Shiquan Sun; Yiwei Lu; Xiaoli Shi; Ziyi Wang; Xuejiao Chen; Guoyong Han; Jie Zhao; Yun Gao; Xuehao Wang
Journal:  Ann Transl Med       Date:  2022-04

8.  A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab.

Authors:  Naoto Saito; Takeshi Hatanaka; Sachi Nakano; Yoichi Hazama; Sachiko Yoshida; Yoko Hachisu; Yoshiki Tanaka; Teruo Yoshinaga; Kenji Kashiwabara; Norio Kubo; Yasuo Hosouchi; Hiroki Tojima; Satoru Kakizaki; Toshio Uraoka
Journal:  Clin Case Rep       Date:  2022-07-25

Review 9.  Liver transplantation for intrahepatic and hilar cholangiocellular carcinoma: Most recent updates in the literature.

Authors:  Susumu Eguchi; Masaaki Hidaka; Takanobu Hara; Hajime Matsushima; Akihiko Soyama
Journal:  Ann Gastroenterol Surg       Date:  2022-03-23

10.  Two Cases of Intraabdominal Bleeding Caused by Hepatocellular Carcinoma Rupture Soon after the Initiation of Chemotherapy with Lenvatinib.

Authors:  Aya Sato; Yukinori Imai; Hiroshi Uchiya; Yoshihito Uchida; Manabu Nakazawa; Kayoko Sugawara; Nobuaki Nakayama; Satoshi Mochida
Journal:  Intern Med       Date:  2022-03-12       Impact factor: 1.282

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.